NCT04197310 2025-01-31Cabozantinib and Nivolumab for Carcinoid TumorsDana-Farber Cancer InstitutePhase 2 Completed19 enrolled 10 charts
NCT03420521 2024-01-09Nivolumab With Ipilimumab in Subjects With Neuroendocrine TumorsSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Terminated9 enrolled 17 charts